Selective inhibitor of the alanine-serine-cysteine transporter 2 (ASCT2 or SLC1A5, IC50 = 9.0 µM rat and 9.6 µM human).1,2 It inhibited the uptake of both glutamine and possibly other amino acids in human cancer cells and reduced in vitro viability by at least 20% in more than half of 29 cancer cell lines screened.2 V-9302 decreased mTOR activity, elevated autophagy, and increased oxidative stress in multiple animal cancer models.2-5
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
